George Abercrombie, a former chief executive officer of Hoffmann-La Roche, has joined the board of directors at BioCryst Pharmaceuticals (Nasdaq: BCRX).

Abercrombie replaces Stephen Biggar, who left the board as of Oct. 10. He had served on the board for six years.

Roche worked at Glaxo Wellcome and also Merck before joining Roche. A graduate of UNC-Chapel Hill with a degree in pharmacy, Abercrombie earned an MBA at Harvard.

In addition to his BioCryst duties, Abercrombie serves on the board at Tranzyme Pharma and is chairman of Brickell Biotech.

Last June, BioCryst said it planned to raise $60 million in new capital. 

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.